| Ansøgningsnr. og dato | 15798264.6 (espacenet) (Federated) (European Patent Register), 20151028 | | Patent/reg.nr. og dato | DK/EP 3212670, 20201223 | | Tilgængelighedsdato | 20170906 | | Prioritetsnr. og dato | US 201462072035 P, 20141029, US 201562157368 P, 20150505, US 201562192025 P, 20150713 | | EP publ. nr. og dato |
EP 3212670 20170906 | | Løbedag | | | Ansøger/indehaver | Bristol-Myers Squibb Company, Route 206 and Province Line Road
Princeton, NJ 08543, US,
Five Prime Therapeutics, Inc., 111 Oyster Point Boulevard
South San Francisco, CA 94080, US | | Ansøgers ref. nr. | V157224DK | | Opfinder | HESTIR, Kevin, Two Corporate Drive
South San Francisco, California 94080, US,
WONG, Brian, Two Corporate Drive
South San Francisco, California 94080, US,
MASTELLER, Emma, Two Corporate Drive
South San Francisco, California 94080, US,
HAMBLETON, Julie, Two Corporate Drive
South San Francisco, California 94080, US,
BELLOVIN, David, Two Corporate Drive
South San Francisco, California 94080, US,
SIKORSKI, Robert, Two Corporate Drive
South San Francisco, California 94080, US,
LEWIS, Katherine E., Rt. 206&Province Line Road
Princeton, New Jersey 08543, US | | Fuldmægtig | Marks & Clerk LLP, 44 rue de la Vallée
BP 1775
L-1017 Luxembourg, LU | | Interessent på tilknyttet sag | | | IPC-Klasse | A61K 39/395 (2006.01) , A61P 35/00 (2006.01) , C07K 16/28 (2006.01) | | Titel/benævnelse | KOMBINATIONSTERAPI MOD CANCER | | Internationalt ansøgningsnr. | US2015057781 | | Internationalt publ. nr. | WO2016069727 | | Relateret sag (certifikat) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
